Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 3/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29555173 | 0.79 | CYP11B1 (0.55) | CYP11B1CYP11B2TDP1 | |
| SCHEMBL29924649 | 0.71 | LMNA (0.39) | MEN1TP53KMT2A | |
| SCHEMBL8970101 | 0.71 | MEN1 (0.51) | MEN1TP53PABPC1KMT2ACSF1R | |
| SCHEMBL27708062 | 0.71 | MEN1 (0.51) | MEN1TP53PABPC1KMT2ACSF1R | |
| SCHEMBL4019974 | 0.68 | MEN1 (0.49) | MEN1TP53PABPC1KMT2ACSF1R | |
| SCHEMBL4019976 | 0.68 | MEN1 (0.49) | MEN1TP53PABPC1KMT2ACSF1R | |
| SCHEMBL4862100 | 0.68 | MEN1 (0.49) | MEN1TP53PABPC1KMT2ACSF1R | |
| SCHEMBL4022616 | 0.68 | MEN1 (0.52) | MEN1TP53PABPC1KMT2ACSF1R | |
| SCHEMBL10684276 | 0.68 | MEN1 (0.49) | MEN1TP53PABPC1KMT2ACSF1R | |
| SCHEMBL5016756 | 0.68 | MEN1 (0.52) | MEN1TP53PABPC1KMT2ACSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497382-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20230391747-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-12-07 | — | — | US | disclosed |
| US-11702404-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702404-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | MEN1 1966/4885TP53 4752/4885PABPC1 2870/4885 |
| US-20230391747-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | MEN1 1966/4885TP53 4752/4885PABPC1 2870/4885 |
| US-12497382-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | MEN1 1966/4885TP53 4752/4885PABPC1 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.